Based on network pharmacology, we found that PRPM might have positive effects on NAFLD, and its beneficial mechanisms of action might involve multiple signaling pathways, such as the HIF-1 signaling pathway, AMPK signaling pathway, AGE-RAGE signaling pathway associated with diabetic complications, insulin resistance, and MAPK signaling pathway. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.